Interview with Christophe Baron, Founder of Louis App: “NFTs to promote disease prevention and longevity”

Questions asked by Alexandre Demailly

We thank Mr Christophe Baron for his time and answers and wish Louis App a long life! To discover the app:

1] Could you introduce your company and the project it is developing?

We started from the fact that life expectancy is decreasing, and that healthy life expectancy is stagnating because of our lifestyles: sedentary lifestyle and bad diet. These habits are not easy to change, and we have tried to find a way to make the user understand that his lifestyle has a direct impact on his life expectancy. (See studies cited at the bottom of the article).

2] Why do you think it is necessary to focus on prevention? Can you tell us more about the “life minutes” concept developed by your company? How was the intellectual property referring to it created?

The adage “il vaut mieux prévenir que guérir” (prevention is better than cure) is not only common sense but also science. Prevention really helps to prevent diseases from appearing. Sometimes people change their lifestyle, but it is too late. Someone who has smoked 20 cigarettes a day for 25 years will take a long time to get their lungs back in good condition and the disease may still set in.

Louis App is a preventive health application that measures your progress through a counter of life minutes gained by eating better and moving more. It is unique and we have filed a patent with the INPI. (Notes from Resolving Pharma:  French National Institute of Intellectual Property)

Today, you can record your physical activity and your meals and measure the impact with a 20-year projection. We are in the process of setting up AI to take a photo of the meal and then the application will recognize the content and the food family. In the same way, in a second version, we are going to offer automatic recovery of physical activity from the smartphone and other devices to reduce data entry to a minimum.

3] How does your app differ from a project like Step’N which encourages users to engage in physical activity but focuses on the financial aspects (including the need for an initial investment)?

StepN is a great app that is aimed at a cryptocurrency savvy audience and requires the purchase of a pair of trainers (Notes from Resolving Pharma: Indeed, the purchase of an NFT – representing a trainer – is required to use the app)

In contrast, the Louis app is aimed at a lay audience in which users will see their progress through levels but also through money: Health and Earn. Furthermore, we consider diet and smoking, which is not the case in StepN.

4] What is the purpose of the NFTs distributed to the users of the application?

This is still being finalized, but it is likely that users will be rewarded with discounts from health, sport and nutrition partners. We are in contact with dieticians who could coach our users with a discounted price. In addition, other highly motivating and understandable rewards are also planned.

5] You will also integrate a token into your project. What will it be used for? What mechanisms will govern its economy?

NFT and tokens will be linked and at this stage we prefer not to say too much. Again, this terminology will not be used, and we will speak a language that everyone can understand.

6] What is the infrastructure blockchain used by your project and what were the arguments that motivated your choice?

The technical choices have not yet been made, we are studying different solutions including Polygon (Notes from Resolving Pharma: Polygon is a second layer solution of the Ethereum Blockchain, which allows transactions to take place on a network with lower fees and higher speed than on the Ethereum Blockchain while maintaining interoperability with it)

7] Do you plan to carry out an ICO/STO/IDO or to use the cryptocurrency universe to find funding (I’m thinking of the grant programmes set up by certain blockchains)?

Yes, an ICO is planned: it will allow us to reward our users, to set up a DAO in order to vote for projects related to R&D (against diabetes for example), it will also allow us to recruit to improve the application and launch new modules; We have just launched a very easy to use diabetes prevention module and plan to launch a heart prevention module, cancer prevention, compliance…. Our road map is very well structured. We know that at least 40% of cancers are caused by our lifestyles and could therefore be avoided!

Very soon we will launch an Ulule campaign to communicate. Please follow us and participate…. There will be a very nice surprise in return.

8] Currently, only 8% of French people hold cryptocurrencies. What do you plan to do to demystify this world for the patients who will use your application?

We will not talk about crypto in the application but about progress linked to prevention through life minutes gained, milestones reached and monetary rewards.

9] What are the pillars on which your company’s business model is based?

The app is free today, but we will move to a freemium model with monthly or annual subscriptions.

10] Projects combining Blockchain and Health are still relatively rare in France. How are Web3 themes perceived in the French health start-up ecosystem?

Some people talk about medical training in the metaverse, health coaching…. I think it is still too early to have a clear vision.

11] What advice would you give to a young entrepreneur wishing to launch a project at the crossroads of Web3 and health?

3 very simple and essential things:

  • Set up a scientific council
  • Don’t hesitate to get coaching
  • Read, be constantly on the lookout

To go further:

These articles should interest you


Introduction to DeSci

How Science of the Future is being born before our eyes « [DeSci] transformed my research impact from a low-impact virology article every other year to saving the lives and…
Illustration In Silico

Towards virtual clinical trials?

Clinical trials are among the most critical and expensive steps in drug development. They are highly regulated by the various international health agencies, and for good reason: the molecule or…

To subscribe free of charge to the monthly Newsletter, click here.

Would you like to take part in the writing of Newsletter articles ? Would you like to take part in an entrepreneurial project on these topics ?

Contact us at ! Join our group LinkedIn !

Entrepreneurship Entrevues

Interview – Molecule, the start-up that wants to revolutionise the financing of drug development with the Blockchain

The Resolving Pharma team is pleased to inaugurate a series of interviews with start-ups creating the pharmaceutical world of tomorrow with this interview with Molecule, a young and ambitious German company willing to change the rules of Drug Development by using Blockchain technology in a new way.

We would like to thank the Molecule team for this exchange and especially Heinrich Tessendorf.

Some of the terms used in this interview are technical and very specific to the field of Blockchain, in order to facilitate the understanding of the project, a glossary has been added at the end of the interview. Do not hesitate to contact us if you have any questions or wish to discuss the subject. Have a good read!

This interview was conducted by Alexandre Demailly and Quentin Vicentini.

Resolving Pharma: With Molecule, you are trying to reinvent, among other things, the financing of pharmaceutical research and development. Can you explain how your platform works?

Molecule: Our platform is a marketplace that moves early-stage IP into web3 via NFTs. This is coupled with frameworks to build biotech DAOs and communities coming together to fund research in specific therapeutic areas. These communities consist of patients, researchers, and enthusiasts.

Practically, all of this comes together when researchers upload a project on our website. From here on forward, other researchers, investors or patient communities can discover these (and other) projects and decide where to invest. Once these role players have decided where to invest, they can connect their web3 wallet (e.g. Metamask) and fund the project by purchasing it as an IP-NFT. IP rights could immediately be transferred to the purchaser and funds could be transferred to the researcher at the exact same time.

Resolving Pharma: What are your company’s goals? What is your vision?

Molecule: Our vision is simple – we see patient, researcher, and investor communities forming to fund and govern end-to-end drug development. We enable this by making IP a highly liquid, data-driven asset class.

Over the next 2+ years, our goal is that our protocol will fund as much R&D as a mid-sized pharma company. With this, we’re ambitious to double our team, launch Molecule V2 and the Molecule DAO, see the first asset out licensed to Pharma, and realize the first patient-led use cases just to name a few.

Our hope is that decentralised biotech will do for access to therapies and medicine what FinTech and Decentralised finance did for how we manage and get access to financial services.

Resolving Pharma: How are submitted projects selected and evaluated? 

Molecule: Projects can be submitted on Molecule’s Discover App or VitaDAO’s Project Submission Form.

On Molecule’s Discover App, any researcher can upload their project and investors can discover them. Currently we have over 300 projects listed on this platform. We, as Molecule, don’t evaluate these projects – it’s up to investors to decide what projects they want to invest in. 

On VitaDAO’s Project Submission Form you can submit your longevity-focused project, but the concept is different in that there, you apply for funding for your project from VitaDAO. We do due diligence in ways similar to how the biopharmaceutical industry currently operates. Namely, they evaluate assets and research as a business opportunity where they’ll take into account market size, competition, team, etc. However, VitaDAO wants to pursue more high-risk and earlier stage projects than those in which traditional funding mechanisms show interest. Also, they want to focus on projects that promote longevity/healthspan/lifespan per se. This is notable because aging isn’t recognized as a disease by government agencies such as the FDA. Therefore, its market can’t be estimated traditionally. They accept this risk and have strategies including pursuing clinical trials in countries with favorable legal framework and/or countries willing to work together to design clinical trials with biomarkers that are relevant to longevity/healthspan/lifespan per se.

Projects submitted for funding through VitaDAO are evaluated by VitaDAO’s scientific evaluation board. They’ll then come up with a suggestion for or against funding. Evaluation is independent of the final decision for funding. If a project qualifies for funding it moves over to an on-chain funding proposal and VitaDAO token holders eventually vote for or against funding the project.

Resolving Pharma: How to invest in a research project using your platform?

Molecule: Currently, every investor needs to be a verified user on Molecule to invest in research projects. To enable you to directly invest in a research project, we need some information from the investor. Our platform is web3 enabled, so once investors have been whitelisted and selected a project they would like to fund it would be similar to how you would purchase an NFT on OpenSea.  Practically, the steps would look like this:

  1. Create an investor account on

  2. Explore research projects in your field of interest. If you want to get in touch with specific researchers that have no contact information listed, feel free to reach out to us via

  3. Get whitelisted for IP-NFT sales: To participate in IP-NFT sales and make binding offers to researchers, Molecule needs to collect certain information from investors. This information will be used primarily to enable investors to sign the underlying legal agreements connected to IP-NFTs. To trigger the whitelisting process, please get in touch with

  4. Bid on IP-NFTs: You are now ready to make offers for new research projects or existing IP-NFTs. We will keep you informed of new funding opportunities arising on Molecule Discovery. If you are interested in funding research projects which are not listed on Molecule yet, feel free to put the researcher in touch with the Molecule team.

  5. Transfer of funds and receiving the IP-NFT: After your bid has been accepted by a researcher, you will be asked to transfer the funds to an escrow account. As soon as the funds are received, the escrow contract will release the IP-NFT to the origin address of the funds.

  6. Manage your IP-NFT: After you have received the IP-NFT, you are now able to manage it on the molecule platform. View the IP-NFT, make selling offers, or review the underlying legal agreement and data (to be added) via the Molecule platform.

Resolving Pharma: How can individual investors choose between different projects?

Molecule: Individual investors will need to do their own due-diligence (DYOR) and consult a scientific advisor. Individuals will most likely choose projects that interest them personally, e.g. someone with a family member living with a certain disease. A lot of the information they require will be on the project page, but they can reach out to individual researchers through the project page on our Discovery app to ask further questions.

In the case where a DAO (e.g. VitaDAO) funds a project, the DAO has a group of subject matter experts (the scientific evaluation board) which advise the DAO on which projects to fund. The decision is then formalised by a governance proposal which is put up to a vote and the final decision is made by all token holders ($Vita in this case). Token holders then vote on these proposals through a simple yes or no vote.

Resolving Pharma: What are the advantages of decentralizing drug development?

Molecule: If IP is siloed and owned by individual companies, these companies could have a very strong bias towards only publishing positive data and this leads to information asymmetry. That’s not how science is supposed to be done. The research community could achieve desired outcomes much faster if research were done more openly and collaboratively. Learning can be done much faster and costs saved by reducing the duplication work through failed experiments. One thing which can help facilitate this is getting attention on research projects through a global public marketplace.

Resolving Pharma: How does your model differ from that offered by crowdfunding platforms?

Molecule: Molecule’s platform is different from crowdfunding, because novel approaches to democratised ownership mean stakeholders can directly co-own the therapies that affect them. Imagine a world where a new insulin treatment is collectively owned by diabetics – what would that do to access and pricing? What if patients could have a direct impact and say in the drugs developed for them? Communities help bring drugs to market through crowd intelligence and curation markets, not just funding, but co-owning.

Resolving Pharma: Can you explain the concept of IP-NFT? How is it secured from a legal point of view?

Molecule: The IP-NFT is a new NFT standard that we’ve developed. IP-NFTs represent the full legal intellectual property rights and provide data access to biopharma research. Think of the IP-NFT as a unique token on the Ethereum blockchain. This token will link to a legal agreement that the researcher will have concluded with investors. Through fractionalization, frictionless transfer, and collateralisation of IP in decentralised financial (DeFi) systems, it unlocks new value in biopharma IP. Fundamentally, IP-NFT enables funding, liquidity and valuation of the IP and research. 

From a legal perspective, the IP-NFT transacts real-world legal rights/licences of the IP. It does this by means of a legal contract and a smart contract that cross-references one another. The legal contract is an IP license with language referencing blockchain transactions, addresses, and signatures. The smart contract is an NFT with code referencing the IP licensing agreement, obfuscating certain data components and storing them on decentralised file storage networks. Combined, the legal contract and the smart contract create the IP-NFT. This gives secure access control to the IP and data to buyers and in the process speeds up due diligence and saves costs. You can learn more about the technical and legal setup of an IP-NFT in this Medium article.

Resolving Pharma: How are decisions made regarding the management of the project’s intellectual property? What is the role of the DAO?

Molecule: VitaDAO is governed by its members. All decisions undergo a pre-defined decision-making process that is inclusive and transparent to all members. Smaller decisions are made informally on VitaDAO’s Discourse forum or Discord, but can be escalated to require an on-chain vote where anyone who owns Vita tokens can vote. Decisions that are contested, have a notable impact on VitaDAO’s stakeholders, affect processes in a fundamental way, or involve a significant use of funds, always undergo an on-chain vote and require a relative majority of token holders to agree.

Resolving Pharma: In this regard, can you introduce us to VitaDAO? How could this project extend human life expectancy?

Molecule: VitaDAO is a decentralised organisation funding longevity research and governing biotech IP and data via IP-NFTs. Think about VitaDAO as the vehicle towards the democratization of access to therapeutics in the biotech world in order to make these assets widely accessible to people across the globe. 

Considering the project’s role in extending human life expectancy, VitaDAO funds early stage research, and could, for example, turn these research projects into biotech companies. As an example, the first project that VitaDAO funded is seeking to validate longevity observations through a series of wet lab experiments and if successful, this work could potentially result in the repurposing of several FDA-approved therapeutics to extend human lifespan, at a lower cost and over faster timelines than conceivably possible with de novo drug discovery.

Resolving Pharma: If our readers want to help you and participate in your projects, what can they do?

Molecule: The best way is to join our Discord, introduce yourself and talk to us there. You can also reach out to our community manager via email at  

If you wish to learn more about the project, you can refer to

  • The company’s website:
  • The company’s Medium blog:
  • As well as the various talks and conferences given by Tyler and Paul, the two co-founders of Molecule: https ://

Glossary :

  • Web3: “Web3 refers to a third generation of the Internet where online services and platforms move to a model based on blockchains and cryptocurrencies. In theory, this means that infrastructures are decentralised and anyone who has a token associated with that infrastructure has some control over it. This model of the web represents a financialised vision of the internet.”
  • NFT for Non-Fungible Token: “An NFT refers to a digital file to which a digital certificate of authenticity has been attached. More precisely, the NFT is a cryptographic token stored on a blockchain. The digital file alone is fungible, whether it is a photo, video or other, the associated NFT is non-fungible.”
  • DAOs: “A DAO (Decentralized Autonomous Organization) is an entity powered by a computer program that provides automated governance rules to a community. The DAO is a complex, smart contract deployed on the Ethereum blockchain, similar to a decentralised venture capital fund. These rules are immutably and transparently written into a blockchain, a secure information storage and transmission technology that operates without a central controlling body. A DAO differs, in theory, from a traditional entity in three ways: it cannot be stopped or closed, no one or no organisation can control it (and thus manipulate its numbers) and, finally, everything is transparent and auditable, all within a supranational framework. A DAO is based on computer code: its operating rules are public and it is not based on any jurisdiction.
  • WhiteList: “The term whitelist defines, in the context of Blockchain projects, a set of people who are assigned a maximum level of freedom or trust in a particular system.

These articles should interest you


Introduction to DeSci

How Science of the Future is being born before our eyes « [DeSci] transformed my research impact from a low-impact virology article every other year to saving the lives and…
Illustration In Silico

Towards virtual clinical trials?

Clinical trials are among the most critical and expensive steps in drug development. They are highly regulated by the various international health agencies, and for good reason: the molecule or…

To subscribe free of charge to the monthly Newsletter, click here.

Would you like to take part in the writing of Newsletter articles ? Would you like to take part in an entrepreneurial project on these topics ?

Contact us at ! Join our group LinkedIn !


Using Real World Data, an interview with Elise Bordet – RWD and Analytics Lead

Every month, Resolving Pharma interviews the stakeholders who shape the health and pharmaceutical industries of tomorrow. In this first interview, Elise Bordet honors us with her participation, many thanks for your time and your insights!

“Data access and analytics capabilities will become an increasingly important competitive advantage for pharmaceutical companies.”

Resolving Pharma] To begin with, could you introduce yourself and talk about your background? Why did you choose to work at the intersection of Data and Pharma?

[Elise Bordet] I am an agronomist, I did a PhD in Immunology-Virology and I then did an MBA before joining my current company. I am passionate about very technical and cutting-edge topics, and the implementation of new research approaches. I was very impressed by a conference on Artificial Intelligence and the notion of a 4th industrial revolution, I didn’t want to miss this subject.

I was very attached to fundamental research in the public sector, but I still wanted to form my own opinion about the pharmaceutical industry, and I am not disappointed at all. I think that it is a great place to contribute to research and the common good.

I love the ever-changing topics, where everything changes on a daily basis, where you always have to challenge yourself to stay updated on the latest innovations. Pharma, Data and AI subjects are heaven for me!

Can you tell us what Real World Data is and how the pharmaceutical industry uses it?

Real World Data is defined as data that is not collected in a randomized clinical trial. Therefore, it is a huge topic. It ranges from data collected in registries to larger databases such as medico-administrative databases.

This data allows the pharmaceutical industry to create drugs that are better adapted to the reality of Health systems. It also allows the creation of new research approaches, to support “drug repurposing” approaches for example.

How do Real World Evidence-based approaches differ from traditional pharmaceutical industry approaches? What are their added values?

Actually, these approaches have existed for a long time, particularly in Pharmacovigilance (the famous Phase IV). However, the amount of data available, its quality, our calculation and analysis capacities have been turned upside down. All these changes allow us to answer new research questions. Questions that remained unanswered because we did not have the capacity to look at what was happening in reality. The second subject is the major contributions of Artificial Intelligence: scientifically, we will be able to go much further.

In your opinion, how is the pharmaceutical industry going to balance the use of Real World Evidence with more traditionally generated clinical and pre-clinical data in the future?

Real World data will play an increasingly important role. Each type of data has its advantages and disadvantages. In fact, it is not a question of opposing data against each other, quite the contrary, the most interesting thing is to be able to bring all these data together and extract the most of information from them.

What impact could this type of data have on the drug value chain and the partnerships that the pharmaceutical industry needs to put in place?

Data access and analysis capabilities will become an increasingly important competitive advantage for pharmaceutical companies. The Data strategy of companies is one of the essential pillars. I imagine that in the future we will look not only at the value of a company’s portfolio, but also at the value and the impact of the analytics that can be performed by the company. Data is going to play so much on the projects’ probability of success that it is difficult to imagine not taking it into account in the metrics of economic valuation.

You recently gave a presentation on digital twin technology. Can you explain what it is?

Digital twin is a very elegant concept that can be summarized as follows: with each development, we generate new data we have to rely on for the next projects. This data should allow us to model most of the levels of biological organization: molecular, cellular, tissular and then at the scale of organs or even of organisms. This modeling will prevent replicating knowledge that has already been created and will notably allow us to accelerate pre-clinical and clinical development, and why not to model the first Phase I results very precisely.

How do you see the pharmaceutical industry in 30 years’ time?

Wow! Everything is going to be different! First of all, I think that, as in all industries, technology will have enabled a profound transformation of all decision making, what we call “data-driven decision making”. Science will have made incredible progress, calculation and prediction capacities will have been multiplied, there will be new approaches in Artificial Intelligence that we do not know today. We will have made immense progress in the interoperability of the various health databases that are fragmented today. It is a good exercise to try projecting ourselves in 30 years’ time. We won’t remember how we did things before, that’s the principle of technological revolutions; we’ve already forgotten how we lived without cell phones and the Internet! We will no longer see ourselves without Data and AI at the center of our decisions and projects. From a more organizational point of view, data sharing will have facilitated public and private scientific collaborations and the implementation of projects that will accelerate research, such as the Health Data Hub in France or the European Health Data Space that will be launched by the European Union.

Do you have any advice for someone who wants to work in Data Science in the Healthcare sector?

We scientists learned through doubt and are still haunted by it. Just because you have expertise in one field (clinical trials, laboratory research, etc.) does not mean that you cannot acquire other skills in Data Science or Artificial Intelligence, for example. Versatile profiles are and will be the most sought after. So my advice is: don’t panic!

If you can, start quickly to train yourself, the Internet puts us at a click of the best courses on programming, Data Science and many other advanced subjects, take advantage of it!

Go ahead and start tomorrow!

These articles should interest you


Introduction to DeSci

How Science of the Future is being born before our eyes « [DeSci] transformed my research impact from a low-impact virology article every other year to saving the lives and…
Illustration In Silico

Towards virtual clinical trials?

Clinical trials are among the most critical and expensive steps in drug development. They are highly regulated by the various international health agencies, and for good reason: the molecule or…

To subscribe free of charge to the monthly Newsletter, click here.

Would you like to take part in the writing of Newsletter articles ? Would you like to take part in an entrepreneurial project on these topics ?

Contact us at ! Join our group LinkedIn !